Index

Note: Page references in *italics* refer to Figures; those in **bold** refer to Tables and Boxes

4-aminopyridine
  in episodic ataxia type 2, 282, 283
5-aminolevulinic acid (5-ALA), 145
acacetazolamide
  in cryptococcal meningitis, 138
acquired pendular nystagmus (APN), 286
acute disseminated encephalomyelitis (ADEM), 116
acute inflammatory demyelinating polyradiculoneuropathy (AIDP), 235, 236–7
acute subdural hematoma (ASD), 93–8
  conservative vs surgical evacuation, **94**
  implications for practice, 95
  implications for research, 95
  nonoperative treatment, 93–4
  objectives, 94
  results, 94–5
  serial CTs, 95–8, **96**
acute traumatic brain injury (TBI), 93–103
    acute subdural hematoma (ASD)(adults), 93–8
    anticonvulsive therapy in, 98
    antiepileptics in, 98–101, **99–100**
    incidence, 93–4
    intracranial hypertension control, 101–3
acyclovir
  in HSV encephalitis, 135
  resistance, 136
albuterol
  in facioscapulohumeral muscular dystrophy, 254
alemtuzumab
  in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 236
alpha-lipoic acid
  in diabetic polyneuropathy, 239–40
Alzheimer’s disease, 77
  agitated behavior in, 180–8
    clinical scenario, 180
    neuroleptics—haloperidol, 182, **183**
    atypical antipsychotics, 182–6, **184–5**
    antiepileptics—valproic acid, 186
antidepressants—SSRIs and trazodone, 186–8, **187**
memantine, 188
  clinical questions, 174–88
  cost of, 173
  framing clinical questions, 174
  incidence, 173
  mild cognitive impairment (MCI), 174–5
  mild to moderate, 176–8
  cholinesterase inhibitors, 176–8, **177**
  clinical problem, 176
  moderate to severe, 178–80
  cholinesterase inhibitor—donepezil, 180, **181**
  clinical scenario, 178
  memantine in, 178–80, **179**
Alzhemed, 175
amino acids
  in amyotrophic lateral sclerosis, 222
aminoglycoside
  in bacterial meningitis, 132
aminopyridines
  in nystagmus, 284–5
amitriptyline
  in migraine, 275
amphotericin B in HIV, 137
ampicillin
  in bacterial meningitis, 132
amygdalohippocampectomy, 166
amyotrophic lateral sclerosis (ALS), 219–30
  assessment of respiratory function, 224–6
  cough assist devices (insufflation/exsufflation), 226–7
  cramps, 229
  diagnosis criteria, **220, 220**
  feeding gastrostomy, 227–8
  framing answerable clinical questions, 219–21
  general approach to search for evidence, 221
  incidence, 219
  invasive assisted ventilation, 226
  multidisciplinary care, 230
amyotrophic lateral sclerosis (ALS) (continued)
NIPPV, 225–6
pain, 229
pharmacological treatment, 221–4
pseudobulbar emotional lability, 229–30
spasticity, 229
symptom control, 229
symptoms, 219
analgesics in migraine, 269
anisocoria, 35
anoxic-ischemic brain injury, 42–3
advanced imaging modalities, 42–3
conventional imaging, 42
CT, 42
diffusion-weighted imaging (DWI), 42
MRI, 42
anterior ischemic optic neuropathy (AION)
arteritic, 291, 293–6
non-arteritic, 291, 296–8, 297, 298
antibiotics
in bacterial meningitis, 131–2
anterograde transport blocking agents, 152
arterial spin labeling MRI, 42
arteritic anterior ischemic optic neuropathy (giant cell arteritis), 113–14
aspirin
in acute ischemic stroke, 56
in secondary stroke prevention, 123–4
assisted death, 15
ataxic breathing, 35
atrial fibrillation
antithrombotics in, 121–3
apixaban, 123
apomorphine, subcutaneous, in Parkinson’s disease, 200
armodafinil (NuVigil)
in narcolepsy, 259
arterial spin labeling MRI, 42
arteritic anterior ischemic optic neuropathy (giant cell arteritis), 113–14
bacterial meningitis, 131–3
corticosteroids, 132
empiric antibiotic therapy, 131–2
prevention, 133
supportive care, 132–3
timing of antibiotics, 131
barbiturates
in intracranial hypertension, 103
behavioral therapy in migraine, 275–6
Belmont Report, 14, 16, 17
beneficence, 14, 16
benign paroxysmal positioning vertigo, 279
benzodiazepines
in delirium, 76, 77
beta-blockers in migraine, 273–5
beta-histine, 281
bifrontal craniectomy (BFC), 90
bipolar disease, 75
Bordin’s Theory of Working Alliance, 312, 314
bovine-derived nerve growth factor (BDNF)
in amyotrophic lateral sclerosis, 222
brain imaging, 18–19
brain tissue oxygen tension (PbtO$_2$), 37
brain tumours, 143–9
brain metastasis, 147
surgical resection, 147
epidemiology, prognostic factors and molecular marker, 143
pre-operative medical management, 143–5
seizures, 144–5
steroids, 143–4
primary tumours, 147
local chemotherapy, 146
systemic chemotherapy, 146
surgical treatment, 145
biopsy vs resection for high-grade glioma, 145
intra-operative imaging, 145
techniques, 145
vs stereotactic radiosurgery (SRS), 148, 149
trial outcome criteria and defining response to therapy, 143
whole brain radiation therapy (WBRT), 147, 148, 149
brainstem ischemia
acquired pendular nystagmus in, 286
branch retinal artery occlusion, 114
bromocriptine in Parkinson’s disease, 194
cabazepine, 168
cabergoline in Parkinson’s disease, 194
Cage, Phineas, 19
calcium-channel blockers in migraine, 275
California Psychotherapy Alliance Scales (CALPAS), 305–7
cannabis
RCVS and, 27
carbamazepine
in acute traumatic brain injury, 101
in epilepsy, 155–7, 158, 159, 169
cardiopulmonary arrest in coma, 39
cataplexy, 261
narcolepsy with and without, 258–9, 260
Index 327

cfotaxime  in bacterial meningitis, 131
ceftazidime, cefepime or meropenem  in bacterial meningitis, 132
ceftriaxone  in bacterial meningitis, 131
Center for Evidence-Based Medicine, 11
central nervous system infections, 131–8
central nervous system tuberculosis, 133–5
additional management considerations, 135
drug resistance, 134
first-line therapies, 133
glucocorticosteroids, 134
HIV-infected patients, 134
surgical interventions, 134–5
central neurogenic hyperventilation, 35
central retinal artery occlusion (CRAO), 114
cephalosporins  in bacterial meningitis, 131–2
cerebellar disorders, 282–3
Cerebral Performance Category (CPC) scale, 39
cerebral perfusion pressure (CPP), 87
cervical artery dissection (CAD), 27
cervical spondylotic myelopathy (CSM), 69–70
Cheyne-Stokes respiration, 35
children
informed consent, 17
cholinesterase inhibitors  in mild cognitive impairment (MCI), 174–5, 175
in mild to moderate Alzheimer's disease, 176–8, 177
in moderate to severe Alzheimer's disease, 180, 181
chronic immune sensory polyradiculopathy (CISP), 235
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 235–6
ciliary neurotrophic growth factor (CNTF)  in amyotrophic lateral sclerosis, 222
ciprofloxacan  in bacterial meningitis, 133
clobazam, 160
clofibrate  in narcolepsy, 259
clozapine  in REM behavior disorder, 263
clopidogrel  in acute ischemic stroke, 57
in stroke, 123–4
in TIA, 62
Cochrane Central Database of Controlled Trials (CENTRAL), 82, 221
Cochrane Central Register Controlled Trials, 93
Cochrane Database of Reviews of Effectiveness, 107, 174, 175, 244
Cochrane Database of Systematic Reviews, 9, 221, 252
Cochrane Epilepsy Group Specialized Register, 82
Cochrane Injuries Group Specialized Register, 93
Cochrane Library, 4, 54, 62, 107, 154, 174, 244
Cochrane Registry, 174
Coenzyme Q10  in migraine, 275
coma, 33–44
ancillary testing, 35
biomarkers, 44
clinical examination and scales, 40–1
comatose TBI patients, 40
comatose postcardiac arrest patients, 40–1
clinical questions, 33
combining parameters to predict outcome, 44
electrophysiology, 43–4
etiologies of, 29, 34
general physical examination, 34
management, 38–40
cardiopulmonary arrest, 39
hypothermia, 39
osmotic therapy, 38–9
pharmacologic agents in, 40
traumatic brain injury, 39–40
monitoring, 35–7, 36
neuroimaging, 41–3
anoxic-ischemic brain injury, 42–3
traumatic brain injury, 41–2
neurologic examination, 34–5
cranial nerves, 34–5
mental status, 34
motor examination, 35
respirations, 35
commensuration, 15
computed tomographic angiography (CTA)
in thunderclap headache, 28, 29
in transient ischemic attack, 61
computed tomography (CT), 61
in anoxic-ischemic brain injury, 42
in headache, 268–9
in migraine, 268–9
in thunderclap headache, 28
Confusion Assessment Method (CAM), 76
Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) tool, 76
Consolidated Standards of Reporting Trials (CONSORT), 10, 11
CONSORT, 10, 11
conventional angiography (CA)
in transient ischemic attack, 61
COREQ, 11
corneal reflex tests, 35
postcardiac arrest, 40–1
corticosteroids  in bacterial meningitis, 132
in brain edema, 60
in chronic immune sensory polyradiculopathy, 235
in Duchenne muscular dystrophy, 249–50
in Guillain–Barré syndrome, 236–7
in intracranial hypertension, 103
in intracranial pressure, 89–90
in multifocal motor neuropathy, 238
in myasthenia gravis, 109, 251
in optic neuritis, 291–3
cranectomy  in brain edema, 60–1
in intracranial pressure, 90, 91
328 Index

creatine
  in amyotrophic lateral sclerosis, 223
critical illness myopathy (CIM), 243
electrodiagnostic testing, 244
critical illness neuropathopathy (CINM), 243–6
  clinical features and diagnosis, 243–4
  clinical scenario, 244
  electrical muscle stimulation (EMS) in, 246
  electrodiagnostic testing, 244
  framing of clinical question and search strategy, 244
  intensive insulin therapy in, 244–5, 245
  physical and occupational therapy in, 245–6
  critical illness polyneuropathy (CIP), 243, 244
  electrodiagnostic testing, 244
critically appraised topic (CAT), 4, 5

cryptococcal meningitis, 136–8
  antifungals in HIV-infected patients, 136–8
  consolidation and maintenance therapy, 137–8
  immune reconstitution syndrome, 138
  induction therapy, 137
  HIV-negative patients, 138
  increased intracranial pressure, 138
  Cryptococcus neoformans, 136
  Cushing reflex, 34
cyclophosphamide
  in chronic immune sensiry polyradiculopathy, 236
  in multifocal motor neuropathy, 238, 239
  in myasthenia gravis, 251
cyclosporine A
  in chronic immune sensiry polyradiculopathy, 236
  in multifocal motor neuropathy, 238
  in myasthenia gravis, 251
cytochrome P450 enzyme inducers and inhibitors, 144
dabigatran, 122
dallampridine, 209, 216
Declaration of Helsinki, 16
decompressive hemicraniectomy (DHC), 90
default mode network (DMN) of brain function, 42
definition of evidence-based medicine (EBM), 17–18
deflazacort
  in Duchenne muscular dystrophy, 249, 250
delirium, 75–8
  diagnosis, 75–6
  evidence-based interventions, 77
  methodology, 76
  NICE recommendations for prevention, 77
  outcome, 77–8
  pharmacologic intervention, 76–7
dementia, 75
  see also Alzheimer's disease
dementia with Lewy bodies, 174
dermatomyositis (DM), 252
Devic's disease, 116
dexamethasone
  in brain tumours, 143, 144
  in polymyositis, 253
  diabetes, stroke and, 120–1
  diabetic polyneuropathy, 235
treatment for, 239–40
diazepam
  in status epilepticus, 82–3, 83–4, 85
diffusion tensor imaging (DTI), 41
diffusion-weighted imaging (DWI)
  in anoxic-ischemic brain injury, 42
  dimethyl fumarate, 214–15
discitis, 68
disease-modifying therapies (DMTs), 209, 210
dizziness, 279
  pharmacotherapy, 279
donepezil, 140, 181
  in delirium, 76, 77
  'do-no-harm' principle (primum non nocere), 13
  Doppler ultrasonography (DUS)
  in transient ischemic attack, 61
downbeat nystagmus (DBN), 283–4
Duchenne muscular dystrophy (DMD), 249
  critical review, 249–50
dipyridamole
  in TIA, 62
electroencephalography (EEG), 35, 37–8
  in coma, 43
  continuous EEG, 37–8, 38
  in delirium, 75–6
  EMBASE, 82
epidural abscess, 68, 69
epilepsy
  aetiology/risk factors, 153
  antiepileptics (AED) in, 154–5
  classification, 153
  definition, 98, 153
  generalised epilepsy, 167–70
  incidence/prevalence, 153
  interventions, 153–4
  methodology, 154
  outcomes, 154
  partial epilepsy treatment, 155–64, 156
  second-line antiepileptics, 160–3, 161–2
  prognosis, 153
  remission, AED withdrawal, 164–6
  early vs late, 165
  rapid vs slow, 165
  seizure risk after, 165
  vs continued treatment, 164–5
  surgery, 166
  amygdalohippocampectomy, 166
  lesionectomy, 166
  temporal lobectomy, 166
  vagus nerve stimulation for drug-resistant epilepsy, 166–7
  episodic ataxia type 2 (EA 2), 282, 283
  EQUATOR Network, 11
  equipoise, 16–17
  ergotamine in migraine, 271, 274
eslicarbazepine acetate, 160
etanercept
  in chronic immune sensory polyradiculopathy, 236
ethics, 13–19
  current framework, 13–16
  empirical evidence in, 17–18
  human subject research, 16–17
  neuroethics, 18–19
evoked potentials in coma, 43–4
Expanded Disability Status Scale (EDSS), 209

facioscapulohumeral muscular dystrophy (FSHD), 249, 253–4
feverfew, 275
fingolimod, 213–214
FLAIR, 41
  in thunderclap headache, 28
fluconazole in HIV, 137
flucytosine in HIV, 137
foscarinet
  in acyclovir resistance, 136
FOUR score scales, 34, 40
free radicals
  in amyotrophic lateral sclerosis, 222
frontotemporal lobar degeneration, 174
functional magnetic resonance imaging (fMRI), 18, 42
  resting-state fMRI, 42
  task-based fMRI, 42

gabapentin
  in amyotrophic lateral sclerosis, 222
  in epilepsy, 157, 159, 160, 163, 170
gentamicin
  in bacterial meningitis, 132
  transtympanic administration of, 281
  vs glucocorticoids, 281
giant cell arteritis (GCA), 113–14, 293–6, 294, 295, 296
Glasgow Coma Scale (GCS), 34, 91, 94
glatiramer acetate, 210, 211–12
glioblastoma multiforme (GBM), 143
Gliolan, 145
glioma
  recursive partitioning analysis for, 144
glucocorticoids
  in CNS tuberculosis, 134
  transtympanic administration of, 281
  vs gentamicin, 281
glycerol in brain edema, 60
GRADE level of evidence, 76–8, 87, 89, 90
teleneurology, 321, 322
Guillain–Barre syndrome, 235, 236–7
haloperidol
  in Alzheimer’s disease, 182, 183
  headache, 267
  classification, 267, 268
  CT scan, 268–9
  primary, 267, 269
  secondary, 267, 269
sentinel, 26
  thunderclap, 23–9
health education
  clinical questions generation, 4
  curriculum, 3–6
  evidence for, 6
  post-tutorial, 5
  resources, 5–6
  educational resource material, 5
  faculty
  informatics, 6
  medical librarians and informatics experts, 5
  space, 5
  time, 5
  topic selection, 4
  tutorial sessions, 4–5
  worksheets, 4–5
Health Insurance Portability and Accountability Act (HIPAA) (2003) (US), 17
health research, 9–11
  clinical research question development, 9
  design, 10
  diagnostic studies, 10–11
  resources for, 11
  therapeutic studies, 10
Herpes simplex virus 1 (HSV-1) encephalitis, 135–6
  acyclovir, 135
  acyclovir resistance, 136
  duration of treatment, 135
  oral antiviral therapy, 136
  steroids, 136
  supportive treatments, 136
Hippocrates, 13
HIV
  antifungals in, 136–8
  CNS tuberculosis and, 134
  interferon gamma b in, 137
HMG CoA reductase inhibitors in stroke, 56–7
Homer’s syndrome, 27
hypersomnia, idiopathic, with and without long sleep time, 262
hyperthermia
  after stroke, 57
  hypnagogic hallucinations, 258
hypothermia
  in coma, 39
  in intracranial pressure, 90–1
‘idiopathic inflammatory myopathies’ (IIM), 253
idiopathic intracranial hypertension (IIH)
  acute visual loss and, 116–17
immune reconstitution syndrome (IRIS), 138
inclusion body myositis (IBM), 252
infantile nystagmus, 287
informed consent, 16, 17
insomnia in Parkinson's disease, 264
institutional review board (IRB) system, 16, 17
insulin
in critical illness neuromyopathy, 244–5
insulin-like growth factor 1 (IGF-1), recombinant human
in amyotrophic lateral sclerosis, 221–2
Intensive Care Delirium Screening Checklist, 76
‘intention-to-treat’ methods, 10
interferon gamma 1b in HIV, 137
interferon-beta, 210, 211
International Classification of Headache Disorders (ICHD-2),
Internet Stroke Center
Stroke Trials Directory, 54, 61
intra-arterial digital subtraction angiography
in intracranial aneurysm, 29
intracerebral hemorrhage, 38
intracranial aneurysms, unruptured, 28
intracranial hypertension, 87–91
acutely traumatic brain injury and, 101–3
causes, 87, 88
methodology, 87
treatment, 88–91, 88
intracranial pressure (ICP)
monitoring, 35–6
normal, 87
raised, 87–91
intravenous immunoglobulin (IVlg), 110–11
vs plasma exchange in myasthenic crisis, 108–9, 111
intravenous immunoglobulin (IVIG)
in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 235
in Guillain–Barre syndrome, 236, 237
in multifocal motor neuropathy, 238–9
isocitrate dehydrogenase (IDH-1), 143
JAMA evidence, 11
jugular bulb oximetry, 36–7
justice, 14, 15
Karnofsky Performance Score (KPS), 144
Kawasaki disease, 114
Kussmaul breathing, 35
lacotamide, 160
lamotrigine
in amyotrophic lateral sclerosis, 222
in epilepsy, 155–7, 158–9, 160, 163–4, 169–70
lesionectomy, 166
levetiracetam
in epilepsy, 157, 159, 160, 164, 170
in status epilepticus, 83
Lewis–Sumner syndrome, 235
LILACS, 93
Limbgirdle muscular dystrophies (LGMDs), 249, 250
listeria meningitis, 132
lithium
in amyotrophic lateral sclerosis, 223–4
locked-in syndrome, 34
lorazepam
in status epilepticus, 82, 83
losigamone, 160–3
magnesium sulfate
in acute traumatic brain injury, 101
magnetic resonance angiography (MRA)
in thunderclap headache, 28, 29
in transient ischemic attack, 61
magnetic resonance imaging (MRI), 61
in anoxic-ischemic brain injury, 42
arterial spin labeling MRI, 42
conventional, 41
functional MRI (fMRI), 42
in optic neuritis, 116
in thunderclap headache, 28
ins tokes, 35
magnetic resonance spectroscopy (MRS), 41
proton MRS, 41
malingerering, 117
mannitol
in brain edema, 59
in coma, 38–9
in intracranial hypertension, 103
in intracranial pressure, 88–9, 91
McDonald criteria, 143
MEDLINE, 82, 93, 174, 191
memantine, 178–80, 179, 188
in moderate to severe Alzheimer's disease, 178–80, 179
Menière's disease, 280–1
meningitis, 26–7
meningoencephalitis, 27
MERCI retrieval system, 55
meropenem
in bacterial meningitis, 132
metastatic spinal cord compression (MSCC), 67–8
methicillin-resistant Staphylococcus aureus, 132
methotrexate
in chronic immune sensiry polyradiculopathy, 236
in polymyositis, 253
methyl-guanine methyl transferase (MGMT), 143
methylphenidate
in indiopathic hypersonnia, 262
methylprednisolone
in traumatic spinal injury, 71
in optic neuritis, 291–3
midazolam
in status epilepticus, 82, 83, 84
migraine, 267–76
analgesics and NSAIDS, 269
antidepressants, 275
antiemetics, 269
antiplatelet drugs/neuromodulators, 275
behavioral therapy, 275–6
beta-blockers, 273–5
calcium-channel blockers, 273
case scenario, 267
critical review of evidence, 268–9
diagnosis, 268
CT scan, 268–9
ergotamine, 271, 274
framing answerable clinical questions, 267–8
herbs and vitamins, 275
nonspecific acute treatments, 269, 270
physical treatments, 275–6
prognosis, 276
prophylaxis, 271–2, 274
triptans, 269–71, 273
vestibular, 282
mild cognitive impairment (MCI), 174
amnestic, 174
cholinesterase inhibitors, 174–5, 175
clinical implications, 175
clinical scenario, 174
homotaurine (Alzhemed), 175
non-amnestic, 174
minocycline
in amyotrophic lateral sclerosis, 222–3
in bacterial meningitis, 133
mismatch negativity (MMN) in coma, 44
mitoxantrone, 209
modafinil
in idiopathic hypersomnia, 262–3
in narcolepsy, 239
motor neuron disease (MND) see amyotrophic lateral sclerosis (ALS)
moxifloxacin
in bacterial meningitis, 132
multifocal motor neuropathy, 235
treatment for, 237–8
multiple sclerosis, 116, 209–17
acquired pendular nystagmus in, 286
alemtuzumab in, 236
attack symptoms, 209
clinically isolated syndrome (CIS), 210
clinical scenario, 210
glatiramer acetate and, 210
interferon-beta and, 210
dalfampridine, 209, 216
disease-modifying therapies (DMTs), 209, 210
methods, 209–10
mitoxantrone, 209
optic neuritis, 291–3, 292
primary progressive multiple sclerosis (PPMS), 209, 216
relapsing-remitting disease (RRMS), 209, 210–12
clinical scenario, 210–11
comparative studies, 212
dimethyl fumarate, 214–15
fingolimod, 213–214
glatiramer acetate and, 210, 211–12
interferon-beta and, 211
natalizumab, 213
teriflunomide, 214
secondary progressive, 215–16
DMTs for, 215–16
Munchausen’s syndrome, 117
muscle-specific kinase (MUSK), 107
mutual causality, 314
myasthenia gravis, 107–11, 249, 250–1
acetylcholine receptors (AChR) and, 107
azathioprine and, 251
clinical scenario, 108, 109
corticosteroids in, 251
framing of clinical question and search strategy, 107
incidence, 107
intravenous immunoglobulin (IVIg) vs plasma exchange in myasthenic crisis, 108–9, 111
IVIg in, 110–11
muscle-specific kinase (MUSK) and, 107
mycophenolate mofetil in, 107, 110
thymectomy in, 109–10, 251–2
*Mycobacterium tuberculosis*, 133
mycophenolate mofetil
in chronic immune sensiry polyradiculopathy, 236
in multifocal motor neuropathy, 239
in myasthenia gravis, 107, 110, 251
narcolepsy with and without cataplexy, 258–9, 260
natalizumab, 213
National Bioethics Advisory Commission, 17
*N. meningitides*, 133
neuroethics, 13, 18–19
neuroleptics
in Alzheimer’s disease, 182, 183
neuromodulators in migraine, 275
neuromyelitis optica (NMO), 116
neuro-oncology, 153–70
evidence-based, 143–9
see also brain tumours; epilepsy
neuro-ophthalmology, 291–8
neuroprotective compounds, 98
in stroke, 57
neurorehabilitation, 303–16
framing clinical questions, 304
searching the evidence, 305
NIH Stroke scale (NIHSS) examination, 322
non-arteritic ischemic optic neuropathy (NA-AION), 113
nonconvulsive seizures (NCSz) in coma, 38
nonconvulsive status epilepticus (NCSE) in coma, 38
non-maleficence, 14
non-physiologic vision loss, 117
nontraumatic spinal cord injury (NTSCI), 67
NSAIDS in migraine, 269
Nuremberg Code, 16
nystagmus, 279, 283, 284–5
acquired pendular nystagmus (APN), 286
downbeat (DBN), 283–4
infantile, 287
periodic alternating (PAN), 286–7
pharmacotherapy, 279
upbeat (UBN), 285–6
Index

obstructive sleep apnea management in stroke, 125
ocular bobbing and dipping, 34
ocular motor disorders
  pharmacotherapy, 279
oculocephalic maneuver, 34
oculopalatal tremor, 286
optic nerve disorders, 116
optic neuritis (ON), 116, 291–3, 292
osmotic therapy in coma, 38–9
osteomyelitis, 68
overlap syndrome, 252
oxcarbazepine, 157, 158, 159, 160, 163, 168
paraldehyde I/M
  in status epilepticus, 83, 84
Parkinson’s disease, 191–204
  clinical questions, 191
  critical review of evidence, 191–204
  deep brain stimulation, 200–4
  early Parkinson’s disease, 191–5
  catechol-O-methyltransferase (COMT) inhibitors, 195
  dopamine agonists, 192–4
  levodopa immediate release, 191–2
  levodopa-controlled release formulations, 192
  MAO-B inhibitors, 194–5
  insomnia in, 264
  levodopa-induced motor complications, 195–200
    amantadine, 197
    COMT inhibitors, 196–7
    continuous duodenal levodopa infusion, 196
    controlled-release levodopa formulations, 195–6
    dopamine agonists, 198–200
    MAO-B inhibitors, 197–8
    levodopa therapy, 191
    search strategy, 191
    symptoms, 191
  REM behavior in, 263
patient–practitioner relationship, 16, 303–16
  brain injury and, 315
    defining, 304
  family and outcome, 314–15
  framing clinical questions, 304
  in neurorehabilitation, 305–12
  searching the evidence, 305, 305
  terminology, 313
  theoretical basis for research, 312–14
Patient Self-Determination Act (1991) (US), 14
penicillin
  in bacterial meningitis, 131, 133
pentobarbital
  in status epilepticus, 84
PENUMBRA system, 55
periodic alternating nystagmus (PAN), 286–7
petasites, 275
phenobarbital
  in acute traumatic brain injury, 101
  in epilepsy, 155, 168
  in status epilepticus, 83, 84
phenobarbital monotherapy in partial epilepsy, 157–8
phenytoin
  in acute traumatic brain injury, 98–100, 101
  in epilepsy, 155, 157–8, 168
  in status epilepticus, 82–3, 84–5
Pick’s disease, 75
PICO acronym, 4
Pinsof’s Integrative Systems Perspective, 313–14
polyarteritis nodosum, 114
polymergocytosis, 249, 252–3
posttraumatic seizures (PTS), 98
pramipexole in Parkinson’s disease, 192–3, 199
prednisolone
  in Duchenne muscular dystrophy, 249
  in Guillain–Barré syndrome, 237
  in multifocal motor neuropathy, 238
  in polymyositis, 252, 253
prednisone
  in chronic immune sensory polyradiculopathy, 236
  in Duchenne muscular dystrophy, 250
  in Guillain–Barré syndrome, 237
  in myasthenic gravis, 251
  in polymyositis, 253
  pregabalin, 163–4
primary intracerebral hemorrhage (PICH), cooling in, 57
primary progressive multiple sclerosis (PPMS), 209, 216
Principles of Biomedical Ethics (Beauchamp and Childress), 13–14, 15
principlism, 14–16
PRISMA, 10, 11
Privacy Rule, 17
propofol
  in status epilepticus, 84, 85
proton MRS, 41
prudent patient standard, 16
Pseudomonas aeruginosa, 132
pseudo-progression, 143, 144
pseudo-response, 143
PubMed, 4, 76, 87, 93, 107, 244, 321
pulse oximetry
  delirium, 76
pupillary light reaction, 40
randomized controlled trial (RCT), 16–17
RANO criteria, 143
rasagiline in Parkinson’s disease, 194–5, 198
relapsing-remitting multiple sclerosis (RRMS), 209, 210–12
REM-behavior in Parkinson’s disease, 263
resting-state fMRI, 42
retinal emboli, 114
retinal vascular occlusion syndromes, 114–17
reversible cerebral vasoconstriction syndrome (RCVS), 27
riboflavin
  in migraine, 275
rifampin
  in bacterial meningitis, 133
riluzole
  in amyotrophic lateral sclerosis, 221
rituximab
  in chronic immune sensory polyradiculopathy, 236
rivaroxaban, 122–3
rivastigamine
in delirium, 76, 77
ropinirole in Parkinson’s disease, 193–4, 198–9
rotigotine in Parkinson’s disease, 194, 199–200
salbutamol
in facioscapulohumeral muscular dystrophy, 254
SAMPLE, 11
selective serotonin reuptake inhibitor (SSRI)
RCVS and, 27
selegiline in Parkinson’s disease, 197–8
sentinel headaches, 26
simvastatin
in acute ischemic stroke, 57
in secondary prevention of stroke, 120
sleep disorders, 257–65
catatexy, 261
framing clinical questions, 257
idiopathic hypersomnia with and without long sleep time, 262
insomnia in Parkinson’s disease, 264
narcolepsy with and without cataplexy, 258–9, 260
REM-behavior in Parkinson’s disease, 263
sleep-disordered breathing and stroke, 257–8
sleep fragmentation, 258
sleep paralysis, 258
smoking cessation, 121
SNOOP4 mnemonic, 269, 269
sodium oxybate in narcolepsy, 259
sodium valproate
in acute traumatic brain injury, 101
in Alzheimer’s disease, 186
in epilepsy, 155, 158, 168, 169
in status epilepticus, 84–5
SOLITAIRE Flow Restoration Device, 55
spinal cord compression, 67–72
degenerative disease, 69–70
infection, 68–9
metastatic (MSCC), 67–8
trauma, 70–1
Spinal Cord Independence Measure III (SCIM III), 71
spinal cord injury without radiographic abnormality (SCIWORA), 71
SPIRIT, 11
spondylitis, 68
spondylodiscitis, 68–9
SSRIs
in Alzheimer’s disease, 186, 187
Standards for Privacy of Individually Identifiable Health Information, 17
Standards for the Reporting of Diagnostic Accuracy Studies (STARD), 10–11
Staphylococcus aureus, 68
STARD, 10–11
status in stroke, 56–7
status epilepticus, 81–5
definition, 81
evidence for questions, 82–5
framing clinical questions, 81–2
eye deviation in, 34
MRI in, 35
sleep-disordered breathing and, 257–8
visual loss in, 115–16
see also stroke, acute ischemic; stroke, secondary prevention of
stroke, acute ischemic, 53–61
brain edema, 59
clinical scenario, 53–4
cooling, 57
critical review of evidence, 54–5
IV thrombolysis, 54–5
mechanical clot retrieval, 55
epidemiology, 53–4
framing clinical questions, 54
management of complications, 57–8
blood glucose control, 59
blood pressure, 58–9
prevention of DVT, 57–8
mechanism and pathophysiology, 53
organization of care, 55–6
treatment, 56–7
stroke, secondary prevention of, 119–26
alcohol, 126
anticoagulants in non-cardiac stroke, 123
antiplatelets without atrial fibrillation, 123–4
antithrombotic agents, 121–3
diabetes, 120–1
diet, 125, 126
dyslipidemia, 120
endarterectomy for symptomatic carotid disease, 124
endovascular treatment (angioplasty and stenting) for carotid stenosis, 125
hypertension in, 119–20
lifestyle management, 125–6
obstructive sleep apnea management, 125
physical activity, 126
smoking cessation, 121
sodium, 125–6
vascular risk factor modification, 119
modifiable vascular risk factors, 119
non-modifiable vascular risk factors, 119
weight reduction, 126
subarachnoid hemorrhage (SAH), 23, 24–6
sumatriptan
in migraine, 269
syndrome of inappropriate antidiuretic hormone release (SIADH), 135
systemic lupus, 114
tacrolimus
  in myasthenia gravis, 251

task-based fMRI, 42
tele-neurology, 321–2
  cost-effectiveness, 322
  feasibility and safety, 321–2
  patient outcomes, 322
  vs neurological examination, 322
telestroke, 321, 322
temozolomide in brain tumor, 143, 146, 147
temporal lobectomy, 166
teriflunomide, 214
Terson’s syndrome, 115

therapeutic connection
  see patient-practitioner relationship

thienopyridine derivatives in stroke, 123–4

thoracic spondylotic myelopathy (TSM), 69–70

thunderclap headache (TCH), 23–9
  advanced noninvasive neuroimaging, 28–9
case scenario, 23
clinical questions, 24
differential diagnosis, 24–7, 26
future research needs, 29
invasive angiography, 29
lumbar puncture, 27–8
primary, 27
secondary, risk of, 24, 25
thymectomy, 109–10, 251–2
  in myasthenia gravis, 251–2

Tia, 163
ticlopidine in stroke, 123–4
topiramate, 157, 158, 159, 163–4, 169
tramiprosate, 175

transesophageal echocardiography (TEE)
  in transient ischemic attack, 61
transient ischemic attack (TIA), 53, 61–3, 119
  ABCD score, 62, 62, 63
  CHADS score, 63
clinical case example, 61
diagnosis, 61
epidemiology, 61
evaluation, 61
framing clinical questions, 62
treatment, 62–3
cardiogenic TIA, 62–3
clinical case example, 63
noncardiogenic TIA, 62
trans-thoracic echocardiography (TTE)
  in transient ischemic attack, 61

trauma
  coma and, 34
  spinal cord compression, 70–1
  traumatic brain injury, 41–2
  advanced imaging modalities, 41
  arterial spin labeling MRI, 42
coma management and, 39–40
  conventional MRI, 41
diffusion tensor imaging (DTI), 41
  functional MRI (fMRI), 42
  magnetic resonance spectroscopy (MRS), 41
  proton MRS, 41
  resting-state fMRI, 42
task-based fMRI, 42
traumatic spinal cord injury (TSCI), 67, 70–1

triazolone
  in Alzheimer’s disease, 186–8, 187

TREVO Retriever, 55
triptans in migraine, 269–71, 273
tuberculosis, CNS, 133–5

Universal Declaration of Human Rights (UN), 16
unresponsive wakefulness syndrome, 33
US Federal Policy for Protection of Human Subjects, 16

vagus nerve stimulation for drug-resistant epilepsy, 166–7, 167
valacyclovir, 136

vancomycin
  in bacterial meningitis, 131, 132
vascular cognitive impairment, 174
vascular dementia (VaD), 173
vegetative state, 33

venlafaxine
  in migraine, 275

venous thromboembolism (VTE), 71
vertigo, 279

pharmacotherapy, 279

vestibular disorders, 279–81, 280
  betahistine, 281
causal therapy, 280
gentamicin, transtympanic administration of, 281
gentamicin vs glucocorticoids, 281
glucocorticoids, transtympanic administration of, 281
improvement of central vestibular compensation, 280
peripheral, 279–80

pharmacotherapy, 279

vestibular migraine, 282

vestibular neuritis, acute, 279–80

vestibular paroxysmia, 281–7, 282, 287
  acquired pendular nystagmus (APN) and oculopalatal tremor, 286
  cerebellar disorders, 282–3
downbeat nystagmus (DBN), 283–4
episodic ataxia type 2 (EA 2), 282, 283
infantile nystagmus, 287

nystagmus, 283, 284–5

periodic alternating nystagmus (PAN), 286–7

upbeat nystagmus (UBN), 285–6

vestibular migraine, 282

betahistine, 281
causal therapy, 280
Index

vidarabine
  in HSV encephalitis, 135
vigabatrin, 163
visual restorative therapy (VRT), 116
vitamins in migraine, 275
voriconazole
  in HIV, 137

warfarin, 121–3
Wegner’s granulomatosis, 114

Whipple’s disease.
  acquired pendular nystagmus in, 286
whole brain radiation therapy (WBRT), 147, 148, 149

xaliproden
  in amyotrophic lateral sclerosis, 223
xanthochromia, 27–8

zonisamide, 163